19 material Form 8-K filings that 18 companies we cover made with the SEC in August 2023, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Innoviva, Inc. announced that Stephen Basso has been appointed Chief Financial Officer, effective August 21, 2023. Basso previously served as CFO and Chief Operating Officer at Cybrexa Therapeutics and has more than 30 years of financial services and pharmaceutical industry experience, and the filing discloses his offer terms, including a $450,000 base salary, a 40% target bonus and an initial option grant of 150,000 shares subject to board approval.
Effective date of August 21, 2023; appointment announced August 25, 2023 in an 8-K and press release
Base salary of $450,000 and annual discretionary bonus with a 40% target of base salary
Initial grant of options to purchase 150,000 shares, subject to Board or Compensation Committee approval, plus a one-time $100,000 signing bonus
If terminated without cause or for good reason, 12 months of base salary continuation and accelerated vesting of unvested options if within 12 months after a change in control
Krystal Biotech disclosed that Andrew Orth, its Chief Commercial Officer, resigned and that his last day with the company was August 2, 2023. The filing does not give a reason for the departure or name a successor, and it does not describe any financial impact.
Andrew Orth, Chief Commercial Officer, resigned from his position.
Orth's last day with Krystal Biotech was August 2, 2023.
The filing does not name a replacement or state a reason for the resignation.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.